NCT01519804 - A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

September 30, 2015

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG

Placebo

Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle

DRUG

cisplatin/carboplatin

standard dose iv, Day 1 of each 21-day cycle, 4 cycles

DRUG

onartuzumab

15 mg/kg iv, Day 1 of each 21-day cycle

DRUG

paclitaxel

200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles

Trial Locations (69)

5417

Daugavpils

12203

Berlin

15232

Pittsburgh

18101

Afula

20133

Milan

26100

Cremona

28007

Madrid

28050

Madrid

28602

Hickory

30060

Marietta

31008

Pamplona

32804

Orlando

33100

Udine

33331

Weston

33435

Boynton Beach

34376

Immenhausen

35033

Rennes

35805

Huntsville

37075

Göttingen

38043

Grenoble

44195

Cleveland

45042

Middletown

46260

Indianapolis

46815

Fort Wayne

46845

Fort Wayne

47303

Muncie

48149

Münster

50009

Zaragoza

55454

Minneapolis

60426

Harvey

60611

Chicago

63110

St Louis

69373

Lyon

70006

Metairie

75674

Paris

78278

Ashkelon

80131

Napoli

81925

München

83100

Avellino

85259

Scottsdale

89148

Las Vegas

90024

Los Angeles

91328

Northridge

92835

Fullerton

93105

Santa Barbara

93309

Bakersfield

93454

San Luis Obispo

94305

Stanford

95817

Sacramento

97701

Bend

98195

Seattle

6093000

Ẕerifin

6423906

Tel Aviv

90095-1772

Los Angeles

81502-1628

Grand Junction

02114

Boston

02215

Boston

C1426ANZ

Buenos Aires

F5300COE

La Rioja

L6304BOC

Santa Rosa

06120

Halle

LV 3401

Liepāja

LV 1079

Riga

LV-1002

Riga

08036

Barcelona

AB25 2ZN

Aberdeen

B9 5SS

Birmingham

BH7 7DW

Bournemouth

LS9 7TF

Leeds